Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio

Core Insights - Knight Therapeutics Inc. has entered into exclusive license and supply agreements with Sumitomo Pharma America Inc. to commercialize MYFEMBREE, ORGOVYX, and vibegron in Canada, along with an asset purchase agreement for certain mature products [1][2] - The Products generated C$11.2 million in revenue for the year ended March 2025, indicating a potential growth opportunity for Knight in the Canadian market [1] - The transaction includes an upfront payment of C$25.4 million, with potential future payments of up to C$15.75 million based on sales milestones, and an estimated C$7 million for inventory [2] Company Overview - Knight Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring and commercializing pharmaceutical products for Canada and Latin America, with shares trading on TSX under the symbol GUD [9] - Sumitomo Pharma Co., Ltd. is a global pharmaceutical company based in Japan, focusing on oncology, urology, women's health, and other therapeutic areas [11] Product Details - MYFEMBREE is the first oral prescription treatment for managing heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with endometriosis, generating approximately C$2.9 million in sales in Canada in 2024 [5] - ORGOVYX is the first oral GnRH receptor antagonist approved in Canada for advanced prostate cancer, with sales of approximately C$1.2 million in 2024 [6] - Vibegron is indicated for the treatment of overactive bladder in the U.S. and works by targeting β3 adrenergic receptors to alleviate symptoms [8]